Table 3.
In Vivo Effects of Poly ICLC on eVLP Vaccination Efficacy
| Vaccine | Dose (μg eVLP) | Survival (%) | Anti-EBOV antibody titer |
|---|---|---|---|
| eVLP | 0.25 | 1/10 (10%) | 800±172 |
| eVLP+Poly ICLC | 0.25 | 8/8 (100%)a | 12,800±4,434b |
| Poly ICLC only | N/A | 1/10 (10%) | 0 |
a
P≤0.05 by log-rank test; bP≤0.05 by 2-tailed Student's t-test.
C57Bl/6 mice were vaccinated i.p. twice, 28 days apart, then challenged with 1,000 pfu mouse-adapted EBOV 28 days after the second vaccination. Poly ICLC was given at 20 μg/dose. Antibody titer is endpoint dilution±standard error.
EBOV, Ebola viruses; eVLP, Ebola virus-like particles; N/A, Not applicable.